Bpifrance views ImCheck’s projects as unique and well-positioned
Marseille, France, August 1, 2019 – ImCheck Therapeutics, a biotech companyon the cutting edge
of the next wave of immunotherapies against cancer and autoimmune diseases, announced the
award of €2 million from Bpifrance to contribute to the development of its most advanced novel
cancer immunotherapy program. With this additional financing, ImCheck has obtained a total of €3.7
million in non-dilutive funding since its €20 million Series A in 2017.
The financing is part of the “Deeptech” fund from Bpifrance and represents both grants and a
reimbursement loan. The support will be dedicated to conducting initial clinical studies of ICT01, a
novel therapeutic anti-BTN3A activating monoclonal antibody designed to promote an anti-tumor
response by γ9δ2 T cells. To date, ICT01 has demonstrated activity in a range of in vitro and in vivo
tumor models.
ImCheck Therapeutics plans on completing all preclinical confirmatory studies before the end of the
year to enable the start of clinical development of ICT01 during the first quarter of 2020. The first
study will be a Phase I dose escalation trial using the anti-BTN3A antibody as a single agent in solid
and hematologic malignancies, followed by a combination study with anti-PD-1/L1 antibodies.
“With the Deeptech program, Bpifrance supports companies in the research and development phase
of a breakthrough innovation closely linked to public/private research with high barriers to entry and
highly differentiated, before its industrial and commercial launch. Bpifrance supports several
companies in the highly-innovative and highly-competitive field of immuno-oncology. We view
ImCheck’s projects as unique and very well-positioned and we are pleased to continue to support
ICT01’s development and its entry in the clinic. This €2m grant follows a first €1m funding awarded
by Bpifrance in July 2017 as part of our Award for Innovation Development program,” said Françoise Marchand, Project Innovation Officer at Bpifrance.
“This new financial support from Bpifrance is a validation of the potential of our pipeline and
recognition of the progress we have achieved in rapidly advancing our first antibody candidate toward clinical evaluation. We remain on target to begin the trial at the start of 2020. Benefiting from the “Deeptech” fund is also an important step for ImCheck as it underlines our innovative position in
immuno-oncology,” concluded Pierre d’Epenoux, CEO of ImCheck Therapeutics.
About IMCHECK THERAPEUTICS
ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies
positioned at the crossroads of two high-potential immunological fields: γ9δ2 T cells and a novel
super-family of immunomodulators, butyrophilins.
Due to their mechanism of action, and notably their ability to simultaneously modulate innate and
adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior
clinical results as compared the first-generation of immune checkpoint inhibitors and when used in
combination overcome the resistance to this group of agents. In addition, preclinical experiments
with antagonist antibodies have demonstrated potential as treatments for a wide-range of
autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel
Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading European investors.
For further information: http://www.imchecktherapeutics.com
« back to overview
For further information: http://www.imchecktherapeutics.com